Biotechnology cancer Clinical Trials

Researchers Use New AI Techniques in Clinical Trials for Personalized Cancer Treatment

Researchers are finding new ways to use artificial intelligence and nanotechnology to enhance treatments, from routine dental techniques to attacking cancerous tissue. At the AVS 65th International Symposium and Exhibition, being held Oct. 21-26, 2018, in Long Beach, California, Dean Ho will present the results of two clinical trials that show how AI-enabled personalized medical treatment for a prostate cancer patient and nanotechnology improved recovery for patients after a root
cancer Cancer Discovery

Analysis of Prostate Tumors Reveals Clues to Cancer’s Aggressiveness

Sequencing reveals genetic errors common in metastatic tumors Using genetic sequencing, scientists have revealed the complete DNA makeup of more than 100 aggressive prostate tumors, pinpointing important genetic errors these deadly tumors have in common. The study lays the foundation for finding new ways to treat prostate cancer, particularly for the most aggressive forms of the disease. The multicenter study, which examined the genomes of tumors that grew and spread
cancer Cancer Discovery

Researchers Find Prostate Cancer Drug Byproduct Can Fuel Cancer Cells

Newly published findings may lead to more personalized prostate cancer therapies A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic. The findings may provide important information for identifying which patients potentially fare better when treated with an alternate therapy. In a newly published study in Journal of Clinical Investigation, researchers found that abiraterone,
cancer Cancer Discovery

Researchers Identify Dozens of New Gene Changes That Point to Elevated Risk of Prostate Cancer in Men of European Descent

 As the result of a six-year long research process, Fredrick R. Schumacher, PhD, a cancer epidemiology researcher at Case Western Reserve University School of Medicine, and an international team of more than 100 colleagues have identified 63 new genetic variations that could indicate higher risk of prostate cancer in men of European descent. The findings, published in a research letter in Nature Genetics, contain significant implications for which men may need
Cancer Discovery

Despite Risk of Breast Cancer, Few Men Undergo Genetic Tests, Study Finds

Cancer is one of the leading causes of death among Americans. At least 10 percent of cancers are caused by inherited mutations in genes such as BRCA1 and BRCA2. Parents with the cancer gene mutation have a 50 percent chance of passing it on to a son or daughter. It’s well-known that women with BRCA are at a very high risk for breast and ovarian cancer. Less known is the
cancer Cancer Discovery

New Metric Defines Areas of Highest Prostate Cancer Burden

To catch prostate cancer at earlier stages, when it’s more easily treated, many institutions do community outreach and education sessions to explain why cancer screenings can be life-saving. In order to have the highest impact, however, institutions must select where to focus their efforts. Prostate cancer is most common among African American men and can be more aggressive in African American and men in a low socioeconomic bracket. Therefore, many
Biotechnology cancer Uncategorized

When Prostate Cancer Reaches Bone, Bone Cells May Drive Overall Growth of the Disease

When prostate cancer metastasizes to bone, it can become especially dangerous – not only with its action in the bone but, interestingly, with increased aggressiveness of the overall cancer itself. Now, research presented at the American Association for Cancer Research (AACR) Annual Meeting 2018 hints at why: Cells involved in these bone metastases may release signals that drive the progression of the disease. “With prostate cancer, often a patient will
cancer Cancer Discovery

Taking a Standard Prostate Cancer Drug with Food Boosts Impact, Lowers Cost

By taking a high-cost drug with a low-fat meal—instead of on an empty stomach, as prescribed—prostate cancer patients could decrease their daily dose, prevent digestive issues and cut costs by 75 percent, according to a new study in the March 28, 2018, issue of the Journal of Clinical Oncology (JCO). Abiraterone acetate, marketed as Zytiga®, is the standard medicine used to treat metastatic castration-resistant prostate cancer. Patients taking Zytiga are told to take
cancer Cancer Discovery

Higher doses of radiation don’t improve survival in prostate cancer

A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. The analysis, which included 104 radiation therapy oncology groups across North America, was led by researchers at Washington University School of Medicine in St. Louis. Past studies have shown that gradually escalating the radiation dose resulted in improved cancer control, such as slower tumor growth
Cancer Discovery

New Prostate Cancer Risk Model Could Better Guide Treatment

One of the biggest challenges in treating prostate cancer is distinguishing men who have aggressive and potentially lethal disease from men whose cancer is slow-growing and unlikely to metastasize. For years, prostate-specific antigen (PSA) level, cancer grade and tumor stage have been used to sort prostate cancer patients into risk groups established by the National Comprehensive Cancer Network. These risk groups help determine treatment course. But the longtime practice has
cancer Cancer Discovery

Huntington’s disease provides new cancer weapon

Patients with Huntington's disease, a fatal genetic illness that causes the breakdown of nerve cells in the brain, have up to 80 percent less cancer than the general population. Northwestern Medicine scientists have discovered why Huntington's is so toxic to cancer cells and harnessed it for a novel approach to treat cancer, a new study reports. Huntington's is caused by an over abundance of a certain type of repeating RNA
cancer Cancer Discovery

Flipping the Switch: Dietary Fat, Changes in Fat Metabolism May Promote Prostate Cancer Metastasis

Prostate tumors tend to be what scientists call “indolent” – so slow-growing and self-contained that many affected men die with prostate cancer, not of it. But for the percentage of men whose prostate tumors metastasize, the disease is invariably fatal. In a set of papers out today in the journals Nature Genetics and Nature Communications, researchers at the Cancer Center at Beth Israel Deaconess Medical Center (BIDMC) shed new light
cancer Cancer Discovery

New Polygenic Hazard Score Predicts When Men Develop Prostate Cancer

An international team, led by researchers at the University of California San Diego School of Medicine, has developed and validated a genetic tool for predicting age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually. The tool, described in the January 11 online issue of the BMJ (formerly the British Medical Journal), may potentially be used to help guide decisions about who to screen for prostate
Biotechnology cancer

Wistar scientists develop novel immunotherapy technology for prostate cancer

A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific protein. This is the first application of the new technology, called DNA-encoded monoclonal antibody (DMAb), for cancer immunotherapy. The study was published online in Cancer Immunology, Immunotherapy. Prostate cancer is the second most common cancer in
Biotechnology cancer Cancer Discovery rare diseases

Prostate Cancer Cells Become ‘Shapeshifters’ to Spread to Distant Organs

Johns Hopkins Kimmel Cancer Center scientists report they have discovered a biochemical process that gives prostate cancer cells the almost unnatural ability to change their shape, squeeze into other organs and take root in other parts of the body. The scientists say their cell culture and mouse studies of the process, which involves a cancer-related protein called AIM1, suggest potential ways to intercept or reverse the ability of cancers to
cancer

Estetrol (E4) Shows Promise as a Safe, Effective Drug for Use in Advanced Prostate Cancer

The natural fetal estrogen estetrol, also called E4, is being tested as a new drug that may help treat advanced prostate cancer, according to an ongoing industry-sponsored study from the Netherlands. The final results will be presented in a poster on Saturday, April 1, at ENDO 2017, the annual scientific meeting of the Endocrine Society, in Orlando, Fla. "E4 for the treatment of prostate cancer would offer a new and
cancer Cancer Discovery Prodrug

First in Human’ Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

Research from Rutgers Cancer Institute of New Jersey examines oral drug that targets cancer cells and spares healthy tissue A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators and colleagues whose research also showed early signs
cancer Clinical Trials

First in Human’ Trial Defines Safe Dosage for Small Molecule Drug ONC201 for Solid Cancer Tumors

Research from Rutgers Cancer Institute of New Jersey examines oral drug that targets cancer cells and spares healthy tissue A ‘first in human’ clinical trial examining the small molecule drug ONC201 in cancer patients with advanced solid tumors shows that this investigational drug is well tolerated at the recommended phase II dose. That’s according to Rutgers Cancer Institute of New Jersey investigators and colleagues whose research also showed early signs
cancer Clinical Trials

Prostate Cancer Clinical Trial Shows Treating with Precision Radiotherapy Reduces Course of Treatment by 50%

An Ontario-led international clinical trial with 1,206 men with localized prostate cancer shows that compressing radiation treatments into four weeks from eight delivers similar outcomes. The findings, published online today in the Journal of Clinical Oncology, provide a new standard of care worldwide, which the participating centres have already adopted, says co-principal investigator Charles Catton, radiation oncologist, Princess Margaret Cancer Centre, University Health Network. Dr. Catton is also a Professor,
cancer

Study Finds Single, Escalated Dose of Brachytherapy Radiation May Be a Safe and Effective Treatment for Localized Prostate Cancer

Option for high-dose-rate brachytherapy marries efficacy of implant-based therapy and convenience of a single treatment Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. The study is available online in the International Journal of Radiation Oncology ● Biology ● Physics,